The concept of TransCard – Translating disease into cardiovascular health
Cardiovascular disease (CVD) is the leading cause of death worldwide. When it comes to possible causes of atherosclerosis as underlying disease, epidemiological studies have provided unequivocal evidence that plasma levels of low-density lipoprotein (LDL) cholesterol and triglycerides are positively correlated with CVD. For high-density lipoprotein (HDL) cholesterol levels this correlation is inverse.
Despite advances in CVD drug development, we are currently still facing a 50-70% residual risk of suffering from CVD, illustrating an urgent need for the identification, characterisation and validation of – in vitro and in vivo models of – novel therapeutically relevant targets. TransCard can efficiently tackle this through combining the expertise and resources of its unique set of industrial and academic partners.